Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMWUQI9)

Drug Name
CER-001 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Phase 2 [1]
Cardiovascular disease BA00-BE2Z Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMWUQI9

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apolipoprotein A-I (APOA1) TT7GN3U APOA1_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Apolipoprotein A-I (APOA1) DTT APOA1 13.036 4.508 4.982 12.009
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute coronary syndrome
ICD Disease Classification BA41
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Apolipoprotein A-I (APOA1) DTT APOA1 8.72E-01 -0.03 -0.45
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01412034) Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Cerenis.